Cellebrite DI (CLBT) Liabilities and Shareholders Equity (2020 - 2025)

Cellebrite DI (CLBT) has reported Liabilities and Shareholders Equity for 6 consecutive years, with $938.9 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Liabilities and Shareholders Equity rose 35.95% year-over-year to $938.9 million; the TTM figure through Dec 2025 stood at $3.3 billion (up 35.96% YoY), while the FY2025 annual figure was $938.9 million, up 35.95% from the prior year.
• Liabilities and Shareholders Equity came in at $938.9 million for Q4 2025 at Cellebrite DI, up from $834.3 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $938.9 million in Q4 2025, with the low at $315.1 million in Q3 2021.
• Average Liabilities and Shareholders Equity over 5 years is $532.5 million, with a median of $503.0 million recorded in 2023.
• Across the five-year window, Liabilities and Shareholders Equity retreated 6.75% in 2021 and soared 41.47% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $339.8 million in 2021, then rose by 18.69% to $403.3 million in 2022, then soared by 32.13% to $532.9 million in 2023, then rose by 29.59% to $690.6 million in 2024, then jumped by 35.95% to $938.9 million in 2025.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $938.9 million, $834.3 million, and $787.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.